AI Article Synopsis
Article Abstract
Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA.
Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks.
Methods: THE FOLLOWING KEYWORDS WERE SEARCHED IN PUBMED AND OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate.
Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate - many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years.
Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621399 | PMC |
| http://dx.doi.org/10.2147/tcrm.s3172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hereditary angioedema (HAE) in children and adolescents: New treatment options.
Allergol Select
October 2024
Hannover Medical School (MHH), Department of Dermatology, Allergology and Venereology, Interdisciplinary Allergy Center of the MHH, Treatment Center for Hereditary Angioedema of the MHH, Hannover, Germany.
Article Synopsis
- Modern management of hereditary angioedema (HAE) emphasizes personalized treatment plans tailored to the needs of children and adolescents, as well as the severity of the disease.
- New medications have improved quality of life for HAE patients, but not all are approved for children, leading to ongoing research into alternative treatments such as those targeting bradykinin effects.
- Emerging options like oral medications, long-acting therapies, and potential gene therapy are being explored to better meet the care requirements for young patients with HAE type I and II.
Uncovering a novel SERPING1 pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema.
Orphanet J Rare Dis
September 2024
Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 The First Ring Road West 2, Chengdu, Sichuan, 610072, China.
Article Synopsis
- Hereditary angioedema (HAE) is a rare genetic condition that causes recurrent swelling and can be life-threatening, with limited ways to predict or prevent attacks.
- A novel mutation in the SERPING1 gene was found in a Han family with HAE, leading to cellular dysfunction due to increased C1-INH levels and subsequent mitochondrial damage.
- Monitoring intracellular calcium levels may provide a new method for predicting HAE attacks, which could improve management strategies for the condition.
[Two pediatric hereditary angioedemathe families: case report and literature review].
Zhonghua Er Ke Za Zhi
September 2024
Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Article Synopsis
- The study looks at two families with a condition called hereditary angioedema, which causes swelling in different body parts, especially in children.
- One girl, age 12, had ongoing stomach pain and was found to have a genetic change related to her condition, while another girl, age 17, had swelling in her limbs and was also diagnosed with a different type of hereditary angioedema.
- Researchers reviewed a lot of information about this condition in kids and found that it can be inherited and often starts showing symptoms between ages 1 and 15.
sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID.
iScience
July 2024
Research and Development Department, Hycult Biotech, Uden, the Netherlands.
Biomarkers for monitoring COVID-19 disease course are lacking. Study aim was to identify biomarkers associated with disease severity, survival, long-term outcome, and Long COVID. As excessive macrophages activation is a hallmark of COVID-19 and complement activation is key in this, we selected the following proteins involved in these processes: PTX3, C1q, C1-INH, C1s/C1-INH, and sMR.
View Article and Find Full Text PDFClinical features and potential markers of disease in idiopathic non-histaminergic angioedema, a real-life study.
Immunol Res
October 2024
Department of Translational Medical Sciences, University of Naples Federico II, Via Sergio Pansini 5, Naples, 80131, Italy.
Article Synopsis
- Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease that causes swelling and doesn't respond well to common medications like antihistamines.
- The study looked at 26 patients with InH-AAE to understand their symptoms and possible markers of the disease, collecting a lot of health-related information.
- Findings included changes in specific proteins in the blood and differences in blood vessel shape, helping to improve the understanding of InH-AAE and possibly leading to better treatments in the future.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!